Lysaker, Norway
Lysaker, Norway

Time filter

Source Type

News Article | May 5, 2017
Site: globenewswire.com

Oslo, 5 May 2017        In accordance with the authorisation granted by the Annual General Meeting 19 May 2016, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 340,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA's choice), at a strike price of NOK 24.95, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The share options are lapsing in Q3 2022. Of these share options, 95,000 share options were allotted to Per Walday, CEO. After the allocation, Per Walday holds a total portfolio of 120,000 unexercised share options and 63,561 shares. 60,000 share options were allotted to Anders Høgset, CSO. After the allocation, Anders Høgset holds a total portfolio of 77,000 unexercised share options and 61,375 shares. 50,000 share options were allotted to Ronny Skuggedal, CFO. After the allocation, Ronny Skuggedal holds a total portfolio of 116,000 unexercised share options and 25,066 shares. 20,000 share options were allotted to Kristin Eivindvik, PD. After the allocation, Kristin Eivindvik holds a total portfolio of 44,500 unexercised share options and 16,867 shares. 15,000 share options were allotted to Gaël L'Hévéder, CBDO. After the allocation, Gaël L'Hévéder holds a total portfolio of 106,000 unexercised share options and 10,000 shares. The current authorisation, as of 19 may 2016, allows for a total of 745,000 share options, of which 735,000 now have been granted by the Board of Directors. For more information, please contact: Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


News Article | May 5, 2017
Site: globenewswire.com

Oslo, 5 May 2017 - PCI Biotech invites to a presentation of the company's first quarter 2017 report on Tuesday 16 May 2017 at Oslo Cancer Cluster Innovation Park. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=52726738), and it will be possible to post questions through the audiocast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 08am CEST on 16 May 2017. For further information, please contact: This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


News Article | May 8, 2017
Site: globenewswire.com

The shareholders of PCI Biotech Holding ASA are invited to attend the Annual General Meeting 2017 at Oslo Cancer Cluster Innovation Park. Please find attached Notice of Annual General Meeting including attendance and proxy forms, executive remuneration statement and the recommendation from the Nomination Committee. The notice including attendance and proxy forms will be sent by mail to all shareholders with known address. The complete notice is available at PCI Biotech's corporate website www.pcibiotech.com. For further information, please contact: This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


News Article | May 5, 2017
Site: globenewswire.com

Oslo, 5 May 2017 - PCI Biotech invites to a presentation of the company's first quarter 2017 report on Tuesday 16 May 2017 at Oslo Cancer Cluster Innovation Park. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=52726738), and it will be possible to post questions through the audiocast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 08am CEST on 16 May 2017. For further information, please contact: This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


Patent
Pci Biotech As | Date: 2013-05-14

The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.


The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitising agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided.


Patent
Pci Biotech As | Date: 2013-03-15

The present invention provides an in vitro method of expressing an antigenic molecule or a part thereof on the surface of a dendritic cell using a PCI method with TPCS_(2a )at a concentration of 0.020-0.1 g/ml, using light of a wavelength of between 400 and 500 nm. Methods of treatment such as vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.


Patent
PCI Biotech AS | Date: 2012-07-05

The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.


Patent
PCI Biotech AS | Date: 2014-08-28

A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.


Patent
PCI Biotech AS | Date: 2014-08-28

A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patients skin. It has a retaining part for retaining the device in place over the region of the patients skin during an activation cycle. A light source is arranged to illuminate the patients skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.

Loading PCI Biotech AS collaborators
Loading PCI Biotech AS collaborators